- AstraZeneca:
Europe Revokes Symbicort COPD Patent
(5/6) MarketWatch
- Merck
& Co. to Cut 1,200 US Sales Jobs
(5/5) Bloomberg.com
- Valeant
to Cut Nearly Half Its Workforce under Restructuring Plan
(5/2) Reuters
- Pfizer
Investing $294M in Irish Biotech Facility
(5/2) Bloomberg.com
- Bristol-Myers
Selling ConvaTec Unit for $4.1B
AP/Forbes.com (5/2)
- Novartis first-quarter
profits surge
Financial Times(4-23)
-
The Long Wait for
Pfizer
Forbes
(4-23)
-
Pfizer CEO Stands by His Plan,
Frustrating Investors
Bloomberg (4-23)
-
U.S. Identifies Tainted
Heparin in 11 Countries
New York Times
(4-23)
-
Genzyme to Build
R&D Center in Beijing
(4-23)
-
GSK Signs Drug
Development Deal With Regulus
San Diego Business Journal
(4-23)
-
GlaxoSmithKline to Buy Sirtris Pharmaceuticals for $720 Million
Market Watch
(4-23)
- FDA
Increases Estimate of Deaths Linked to Contaminated Heparin
(4/9) The Washington Post
-
Why
You Can't Tell Where Your Medication Was Made
(4/8) The
Wall Street Journal
-
Novartis
May Spend Up To $39B for Nestlé’s Stake in Alcon
(4/7) BusinessWeek
-
Bristol-Myers:
A Hot Takeover Target?
(4/7) BusinessWeek
-
Sanofi
Seeks Research Partners in China
(4/4) The Wall Street Journal
-
Schering-Plough
Announces Cost-Cutting Program
(4/2) Reuters
-
Shares
of Schering-Plough, Merck & Co. Fall On Blow to Cholesterol Drugs
(3/31) Reuters
-
Cell
Genesys Snags Up to $320M in Cancer-Therapy Pact with Takeda
(3/31) Business Wire
-
Lechleiter
Takes Lilly's Helm: What's In Store?
(3/30) AP/BusinessWeek
-
Overseas
Drugs Hit U.S. Regulatory Snags
(3/26) The Wall Street Journal
-
Pfizer
Seeking to Extend Lipitor Exclusivity To 2016
(3/26) MarketWatch
-
Profitable
Year for Bristol-Myers, Abbott Execs
(3/24, 3/20) The Wall Street Journal Health Blog
-
Novartis
Head of Global Drug Development Is Leaving
(3/20) The Wall Street Journal Health Blog
-
Takeda,
Abbott Splitting Joint US Venture; Abbott to Receive About $1.5B
(3/20) Forbes.com
-
Presidio
Paying Up To $108M for XTL's HCV Program
(3/20) Presidio Pharmaceuticals
-
Survey:
Drugmakers May Scale Back R&D Investment in Britain
(3/19) Reuters
-
Scientists
Identify Heparin Contaminant
(3/19) Reuters, The New York Times
-
Takeda
Reportedly Buying Out Abbott’s Stake in US Joint Venture;
Abbott Hit by Antitrust Suit
(3/19, 3/18) Reuters
-
AstraZeneca,
Pfizer Rumored To Be Sizing Up Shire
(3/18) Bloomberg.com
-
GSK
Experimenting With Tiered Pricing
(3/17) Forbes.com
-
Are
High Doses of Expensive Drugs Always Warranted?
(3/16) The New York Times
-
Pfizer,
Wyeth CEOs See Drop In Compensation
(3/14, 3/13) The Wall Street Journal Health Blog
-
Lilly,
Transition Therapeutics Ink Diabetes Deal
(3/13) Transition Therapeutics
-
IMS
Health: Overall Sales Growth in the US Rx Market Moderated in 2007
(3/12)
IMS
-
Are
Drugmakers Becoming More Vulnerable to Losing Patents?
(3/11) Financial Times
-
Notes
from Pharma's Executive Suites
(3/10) AP/BusinessWeek; (3/6) Bloomberg.com; (3/5) Reuters
-
Amgen,
Kyowa Hakko Ink mAb Deal Worth Up To $520M
(3/6) Kyowa Hakko
-
Heparin
Mimic Found in Baxter Product
(3/6) The New York Times
-
FDA
Decisions on Drug Approval Could Start Slipping
(3/5) The Wall Street Journal Health Blog
-
Pfizer
Answers Critics with New Rx
(3/5) Reuters; (3/4) The Wall Street Journal
-
Pfizer
Buying Serenex, Inc.
(3/3) Business Wire
-
GSK
Cutting Jobs in North Carolina
(2/29) The Charlotte Observer
-
More
Deaths Possibly Linked to Baxter's Heparin
(2/29) The New York Times
-
Amgen
Temporarily Prevails in Legal Battle with Roche
(2/28) CNNMoney.com
-
China
Says Importing Countries Bear Responsibility for Drug Checks
(2/27) The Wall Street Journal
-
Week's
Top Deals Total Up to $2.6B
(2/26, 2/25, 2/21, 2/20) Company press releases
-
Elan
Reportedly Considering a Spin-off
(2/24) Reuters
-
White
House Wants to Widen FDA Authority Over Imports
(2/23) The Wall Street Journal
-
New
Novartis Research Institute to Focus on Vaccines for the Developing World
(2/22) Novartis
-
GSK
Announces Layoffs in England, Ireland
(2/22) BBC News; (2/21) Belfast Telegraph
-
Pfizer
Buying Encysive for $195M
(2/20) Business Wire
-
Judge
Reduces Award by $76M in Wyeth Case
(2/19) AP/CNNMoney.com
-
Fujifilm
Buying Toyama Chemical for $1.4B, Gaining Experimental Flu Drug
-
(2/19)
Bloomberg.com
-
FDA
Failed to Inspect Chinese Maker of Heparin Ingredient Linked to Deaths;
House Democrat Calls for FDA Commissioner's Resignation
(2/18) Bloomberg.com; (2/15) AP/Los Angeles Times
-
Actavis
Recalls Certain Fentanyl Patches
(2/17) Actavis
-
Buffett
Bolsters GSK, Sanofi-Aventis
(2/15) Forbes.com
-
AstraZeneca
Spins Off Gastrointestinal Unit
(2/14) MarketWatch
-
Novartis
Head Is Returning to J&J
(2/14) Reuters
-
FDA
Adds Depression as Possible Side Effect of Cholesterol Meds
(2/14) CNNMoney.com
-
Bayer
Warns Doctors of Potential Avelox Side Effects
(2/14) Reuters
-
FDA
Issues Warning on Pfizer's Anti-Smoking Drug
(2/14) CNNMoney.com
-
Johnson
& Johnson Recalls Certain Fentanyl Patches
(2/12) Johnson & Johnson
-
Pfizer
Earmarks $189M for Inhaled Drugs Unit
(2/12) Reuters
-
Merck
& Co. Teaming With Dana-Farber on Cancer Drug Development
(2/12) Dana-Farber Cancer Institute
-
Dyax,
Sanofi Strike Antibody Deal Worth Up To $500M;
Human Genome Sciences, Xencor Ink Antibody Pact
(2/12)
Business Wire; (2/7) Xencor
-
AstraZeneca
Exploring Options for Some Research Projects
(2/11) Reuters
-
Sanofi
Rumored to Be Eyeing Oxford BioMedica
(2/11) Reuters
-
Merck
& Co. Paying $650M to Settle Medicare Cases
(2/7) MarketWatch
-
AstraZeneca
Cutting 300 Jobs
(2/6) Macclesfield Express
-
GlaxoSmithKline
in $425M Licensing Deal with Amira Pharmaceuticals
(2/4) Amira
-
Amgen
Inks $1.2B Deal with Takeda
(2/3) Takeda
